# Larazotide

Source: https://aminodesk.com/library/larazotide
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Larazotide is an oral peptide that was tested as an add-on to the gluten-free diet in celiac disease. It is now sold as a "leaky gut" peptide and added to some blends. Its Phase 3 trial was stopped in 2022 because the interim results showed it was unlikely to succeed.

- **Legal lane:** not FDA-approved. Not on the list of substances pharmacies may compound.
- **Evidence grade:** B. Real trials in people; the largest was stopped for lack of effect.
- **Form:** capsule by mouth in the trials
- **Established human dose:** none

## What it is

Larazotide acetate, also called AT-1001, is a chain of eight amino acids. It was designed to tighten the junctions between the cells that line the gut, so that less gluten slips through. It was the first celiac drug candidate to reach Phase 3.

## What the evidence shows

- **Phase 2:** a trial in 342 adults with celiac disease who had been on a gluten-free diet for at least 12 months found that one of the doses tested reduced symptoms.
- **Phase 3:** the CedLara trial enrolled people who still had symptoms on a gluten-free diet. In June 2022 an interim analysis found the difference from placebo was not statistically significant, and that the number of extra patients needed to show an effect was too large to continue. The company stopped the trial.

No trial has tested it for the general gut, skin or inflammation claims it is sold for.

## Legal status

- Not FDA-approved for any use. One summary reports no active development program as of 2026.
- Not on the FDA's list of bulk substances pharmacies may compound.
- It is not one of the six peptides in the October 2026 policy.

## Reported dosing

**No dose has been established.**

Development ended before an approved dose was set, and the positive Phase 2 result was at a single dose level that the larger trial did not confirm. The trials used capsules. No trial has tested it by injection, which is how blends deliver it.

## Safety

- The trials did not raise major safety concerns, but they tested capsules, in celiac patients, for limited periods.
- Injecting it, alone or in a blend, is untested.
- Products sold as research chemicals have no verified contents or sterility.

## Common questions

### Is larazotide approved for celiac disease?

No. Its Phase 3 trial was stopped in 2022 and it is not FDA-approved for anything.

### Why was the larazotide trial stopped?

An interim analysis found no statistically significant benefit, and continuing would have needed far more patients than was feasible.

### Does larazotide fix leaky gut?

No trial has tested that claim outside celiac disease.

## Sources

- [BioSpace: interim results end the Phase 3 trial of larazotide](https://www.biospace.com/poor-results-end-9-meters-phase-iii-trial-for-larazotide)
- [Beyond Celiac: Phase 3 study of larazotide discontinued](https://www.beyondceliac.org/research-news/phase-3-study-discontinued/)
- [Beyond Celiac: the earlier Phase 2 trial in 342 adults](https://www.beyondceliac.org/?p=19290)
- [Superpower: larazotide acetate status and evidence](https://superpower.com/guides/peptides/larazotide-acetate)
- [PeptideGrids: compounding status and development status](https://peptidegrids.pages.dev/compound/larazotide/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
